Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised controlled trial.

MLA

Stein, Evan A., et al. “Effect of a Monoclonal Antibody to PCSK9, REGN727/SAR236553, to Reduce Low-Density Lipoprotein Cholesterol in Patients with Heterozygous Familial Hypercholesterolaemia on Stable Statin Dose with or without Ezetimibe Therapy: A Phase 2 Randomised Controlled Trial.” Lancet (London, England), vol. 380, no. 9836, July 2012, pp. 29–36. EBSCOhost, https://doi.org/10.1016/S0140-6736(12)60771-5.

APA

Stein, E. A., Gipe, D., Bergeron, J., Gaudet, D., Weiss, R., Dufour, R., Wu, R., & Pordy, R. (2012). Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised controlled trial. Lancet (London, England), 380(9836), 29–36. https://doi.org/10.1016/S0140-6736(12)60771-5

Chicago

Stein, Evan A, Dan Gipe, Jean Bergeron, Daniel Gaudet, Robert Weiss, Robert Dufour, Richard Wu, and Robert Pordy. 2012. “Effect of a Monoclonal Antibody to PCSK9, REGN727/SAR236553, to Reduce Low-Density Lipoprotein Cholesterol in Patients with Heterozygous Familial Hypercholesterolaemia on Stable Statin Dose with or without Ezetimibe Therapy: A Phase 2 Randomised Controlled Trial.” Lancet (London, England) 380 (9836): 29–36. doi:10.1016/S0140-6736(12)60771-5.